Inactive

SOURCES SOUGHT NOTICE: Acquisition of a CytKick Max Autosampler Notice Number: 75N91020Q00127 Issued By: National Cancer Institute (NCI), Office of Acquisitions (OA) http://www.nci.nih.gov or http://r... SOURCES SOUGHT NOTICE: Acquisition of a CytKick Max Autosampler Notice Number: 75N91020Q00127 Issued By: National Cancer Institute (NCI), Office of Acquisitions (OA) http://www.nci.nih.gov or http://rcb.cancer.gov/rcb-internet/ Key Dates: Capability Statement Due Date: July 20, 2020 by 12:00PM EST This Small Business Sources Sought Notice (SBSS) is for information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the National Cancer Institute (NCI). The purpose of this Sources Sought Notice is to identify qualified Small Business concerns including 8(a), HUBZone or Service-Disabled Veteran-owned businesses that are interested in and capable of performing the work described herein. The NCI does not intend to award a contract on the basis of responses received nor otherwise pay for the preparation of any information submitted. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This requirement is assigned North American Industry Classification System (NAICS) code 334516 with a size standard of 1000 employees. As a result of this Sources Sought Notice, the NCI may issue a Request for Quotation (RFQ). THERE IS NO SOLICITATION AVAILABLE AT THIS TIME. However, should such a requirement materialize, no basis for claims against NCI shall arise as a result of a response to this Sources Sought Notice or the NCI’s use of such information as either part of our evaluation process or in developing specifications for any subsequent requirement. The Laboratory of Tumor Immunology and Biology (LTIB) functions as a multidisciplinary and interdisciplinary translational research programmatic effort with the goal of developing novel immunotherapies for cancer. The LTIB strategic plan focuses on the development of novel immunotherapeutic for human carcinomas not only as monotherapies but more importantly in combination with other immune-mediating modalities and other conventional or experimental therapies as part of an immuno-oncology programmatic effort. Within this effort are several research groups, a clinical trials group, three independent tenured Senior Investigators and multiple collaborations with intramural and extramural scientific and clinical investigators and with investigators in the private sector. The program takes advantage of the uniqueness of the NCI intramural program in that it spans high-risk basic discovery research in immunology and tumor biology, through preclinical translational research, to paradigm-shifting clinical trials. Our focus is on the design and development of novel 'off-the-shelf' recombinant vaccines and immunomodulatory that can be used in clinical studies at numerous institutions, and do not involve costly and labor-intensive ex vivo manipulations that can only be performed one or two centers. This is accomplished via Cooperative Research and Development Agreements (CRADAs) with partners in the private sector that provide agents for preclinical studies in appropriate animal models that we have developed and in human in vitro systems. The immunotherapeutics that we have developed have also enabled collaborations with other clinical investigators at extramural Cancer Centers. As part of NCI’s research effort, the CytKick Max Autosampler is an accessory product to the Attune NxT flow cytometer which is currently in use within the LTIB. The CytKick Max Autosampler is an instrument which will allow scientists within the LTIB to more rapidly and easily acquire data from NCI’s experiments in which NCI performs immunologic monitoring of immune responses in our pre-clinical animal models. These experimental procedures are an essential aspect of our research program, which provides the pre-clinical rationale for all the clinical trials performed by the LTIB. This will be issued as a Non-Severable Firm Fixed-Price Purchase Order. The following product features/characteristics are required for this requirement: Instrument must be compatible with the brand name AttuneNXT Flow Cytometer and associated software which is currently in use within the LTIB. Instruments must be capable of acquiring data from all wells of a 96-well plate in under 25 minutes. The instrument must have less than 0.5% carry-over between samples. The instrument must be able to mix samples via aspiration. The instrument must be able to acquire samples from the following vessels. 96 deep-well (flat, U-bottom and V-bottom) 384 deep-well (flat, U-bottom and V-bottom) Racks for 1.5 and 2 mL centrifuge tubes The instrument must have external fluid storage. The instrument must be compatible with passive cooling for 96-well U-bottom plates. The instrument must be able to perform an auto calibration. Must include a minimum of 12-month warranty for main components and part, unless indicated otherwise. Shipping charges must be included in the quote. NCI will not be responsible in the event charges are not included in the quote. Note: NCI plans to award a contract that has FOB origin delivery terms. The vendor will provide in-building delivery, The vendor will deliver and install the instrument at the following location: The vendor will supply the instrument within 4 weeks of receiving the order. The vendor will provide 4 hours of on-site training on how to use and maintain the instrument and associated software. How to Submit a Response: Page Limitations: Interested qualified small business organizations should submit a tailored capability statement for this requirement not to exceed 10 single sided pages including all attachments, resumes, charts, etc. (single spaced, 12-point font minimum) that clearly details the ability to perform the requirements of the notice described above. All proprietary information should be marked as such. Responses should include a minimum of a one page resume of the individuals meeting the requirements, and up to two pages demonstrating experience over the past two years meeting the requirements of this notice. Statements should also include an indication of current small business status; this indication should be clearly marked on the first page of your capability statement (preferable placed under the eligible small business concern’s name and address). Responses will be reviewed only by NIH personnel and will be held in a confidential manner. Organizations shall demonstrate 1.) Technical Approach 2.) Personnel Requirements and Organizational Experience. Due Date: Capability statements are due no later than July 20, 2020 by 12:00PM EST Delivery Point: All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the unique specifications described herein. All questions must be in writing and emailed to David.Romley@nih.gov. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA) through sam.gov. No collect calls will be accepted. Please reference number 75N91020Q00127 on all correspondence. Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a RFQ may be published in Fed Biz Opps. However, responses to this notice will not be considered adequate responses to a solicitation(s). Point of Contact: Inquiries concerning this Notice may be direct to: David Romley at David.Romley@nih.gov. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation.